Most studies investigate the ICD-inducing effect of co-treatment with multiple common chemotherapeutics, such as anthracyclines, cyclophosphamide, oxaliplatin, paclitaxel, 5-fluorouracil and immune-check-point inhibitors (Jiang et al., 2021) or passive tumor-targeting immunotherapies, such as trastuzumab (anti-human epidermal growth factor receptor 2). Here, ERBB2 is linked to neoplasm.